Similar articles for PMID: 25466361

Year	Number of Results
1936	1
1977	1
1980	2
1982	2
1983	1
1991	1
1992	2
1993	1
1994	2
1995	2
1996	2
1997	5
1998	6
1999	3
2000	5
2001	5
2002	9
2003	7
2004	5
2005	8
2006	5
2007	7
2008	4
2009	5
2010	8
2011	10
2012	11
2013	8
2014	14
2015	17
2016	11
2017	10
2018	9
2019	13
2020	7
2021	8
2022	4
2024	0

1

The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer.

D'Alimonte L, Helou J, Sherman C, Loblaw A, Chung HT, Ravi A, Deabreu A, Zhang L, Morton G. D'Alimonte L, et al. Brachytherapy. 2015 May-Jun;14(3):309-14. doi: 10.1016/j.brachy.2014.10.003. Epub 2014 Nov 25. Brachytherapy. 2015. PMID: 25466361

2

A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.

Joseph N, Taylor C, O'Hara C, Choudhury A, Elliott T, Logue J, Wylie J. Joseph N, et al. Radiother Oncol. 2016 Nov;121(2):299-303. doi: 10.1016/j.radonc.2016.09.016. Epub 2016 Oct 28. Radiother Oncol. 2016. PMID: 28029404 Clinical Trial.

3

High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success.

Helou J, D'Alimonte L, Loblaw A, Chung H, Cheung P, Szumacher E, Danjoux C, Ravi A, Deabreu A, Zhang L, Morton G. Helou J, et al. Radiother Oncol. 2015 Apr;115(1):84-9. doi: 10.1016/j.radonc.2015.02.023. Epub 2015 Mar 11. Radiother Oncol. 2015. PMID: 25770875

4

Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.

Schroeder C, Geiger F, Siebert FA, Baumann R, Bockelmann G, Schultze J, Kimmig B, Dunst J, Galalae R. Schroeder C, et al. Brachytherapy. 2019 Jan-Feb;18(1):8-12. doi: 10.1016/j.brachy.2018.08.013. Epub 2018 Oct 25. Brachytherapy. 2019. PMID: 30482622

5

Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.

Kestin LL, Goldstein NS, Vicini FA, Martinez AA. Kestin LL, et al. J Urol. 2002 Nov;168(5):1994-9. doi: 10.1016/S0022-5347(05)64280-2. J Urol. 2002. PMID: 12394693

6

Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.

Ellis RJ, Vertocnik A, Kim E, Zhou H, Young B, Sodee B, Fu P, Beddar S, Colussi V, Spirnak JP, Dinchman KH, Resnick M, Kinsella TJ. Ellis RJ, et al. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):362-70. doi: 10.1016/s0360-3016(03)00588-1. Int J Radiat Oncol Biol Phys. 2003. PMID: 12957246

7

PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.

Ko EC, Stone NN, Stock RG. Ko EC, et al. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. doi: 10.1016/j.ijrobp.2011.07.009. Epub 2011 Oct 8. Int J Radiat Oncol Biol Phys. 2012. PMID: 21985944

8

Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.

Chen WC, Tokita KM, Ravera J, Fu P, Jiang Y, Kaminsky DA, Ponsky L, Ellis RJ. Chen WC, et al. Brachytherapy. 2013 Sep-Oct;12(5):422-7. doi: 10.1016/j.brachy.2012.09.003. Epub 2013 Feb 4. Brachytherapy. 2013. PMID: 23380382

9

Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.

Kestin LL, Goldstein NS, Vicini FA, Mitchell C, Gustafson GS, Stromberg JS, Chen PY, Martinez AA. Kestin LL, et al. Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):107-18. doi: 10.1016/s0360-3016(02)02925-5. Int J Radiat Oncol Biol Phys. 2002. PMID: 12182980

10

Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.

Dibiase SJ, Hussain A, Kataria R, Amin P, Bassi S, Dawson N, Kwok Y. Dibiase SJ, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):732-6. doi: 10.1016/j.ijrobp.2010.06.042. Epub 2010 Oct 30. Int J Radiat Oncol Biol Phys. 2011. PMID: 21036486 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

190 results

Results by year